Edenred SE (EPA:EDEN)
France · Delayed Price · Currency is EUR 25.12
-0.43 (-1.68%)
Jul 31, 2025, 5:35 PM CET
CTI BioPharma Cash Flow Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 507 | 507 | 267 | 386 | 313 | 238 | Upgrade |
Depreciation & Amortization | 248 | 225 | 193 | 149 | 132 | 125 | Upgrade |
Loss (Gain) From Sale of Assets | 8 | 8 | - | 9 | 19 | 4 | Upgrade |
Asset Writedown & Restructuring Costs | 15 | 15 | 11 | 18 | 16 | 26 | Upgrade |
Loss (Gain) on Equity Investments | 1 | 5 | 3 | -2 | -8 | -13 | Upgrade |
Stock-Based Compensation | 24 | 28 | 21 | 20 | 12 | 14 | Upgrade |
Other Operating Activities | 58 | 24 | 151 | 43 | 14 | 27 | Upgrade |
Change in Accounts Receivable | 24 | 24 | - | - | - | - | Upgrade |
Change in Inventory | 5 | 5 | - | - | - | - | Upgrade |
Change in Accounts Payable | 140 | 140 | - | - | - | - | Upgrade |
Change in Income Taxes | -12 | -12 | - | - | - | - | Upgrade |
Change in Other Net Operating Assets | -185 | 22 | 365 | 359 | 76 | 269 | Upgrade |
Operating Cash Flow | 872 | 1,029 | 1,052 | 1,013 | 604 | 718 | Upgrade |
Operating Cash Flow Growth | -20.22% | -2.19% | 3.85% | 67.72% | -15.88% | 54.41% | Upgrade |
Capital Expenditures | -214 | -217 | -190 | -151 | -114 | -104 | Upgrade |
Sale of Property, Plant & Equipment | 25 | 23 | 12 | 29 | 25 | - | Upgrade |
Cash Acquisitions | -396 | -504 | -1,036 | -77 | -72 | -127 | Upgrade |
Investment in Securities | -5 | -6 | -14 | -12 | -19 | -63 | Upgrade |
Investing Cash Flow | -590 | -704 | -1,228 | -211 | -180 | -294 | Upgrade |
Short-Term Debt Issued | - | 120 | - | - | - | - | Upgrade |
Long-Term Debt Issued | - | 505 | 1,198 | 10 | 416 | 633 | Upgrade |
Total Debt Issued | 727 | 625 | 1,198 | 10 | 416 | 633 | Upgrade |
Short-Term Debt Repaid | - | - | -493 | -597 | -335 | -812 | Upgrade |
Long-Term Debt Repaid | - | - | -255 | - | - | -6 | Upgrade |
Total Debt Repaid | -284 | - | -748 | -597 | -335 | -818 | Upgrade |
Net Debt Issued (Repaid) | 443 | 625 | 450 | -587 | 81 | -185 | Upgrade |
Issuance of Common Stock | 2 | 2 | - | - | - | 3 | Upgrade |
Repurchase of Common Stock | -242 | -359 | -25 | -2 | -41 | -23 | Upgrade |
Common Dividends Paid | -289 | -271 | -249 | -224 | -60 | -60 | Upgrade |
Other Financing Activities | -39 | -36 | -29 | -15 | -37 | -21 | Upgrade |
Financing Cash Flow | -125 | -39 | 147 | -828 | -57 | -286 | Upgrade |
Foreign Exchange Rate Adjustments | -112 | -73 | -1 | -10 | 10 | -74 | Upgrade |
Net Cash Flow | 45 | 213 | -30 | -36 | 377 | 64 | Upgrade |
Free Cash Flow | 658 | 812 | 862 | 862 | 490 | 614 | Upgrade |
Free Cash Flow Growth | -25.65% | -5.80% | - | 75.92% | -20.20% | 69.61% | Upgrade |
Free Cash Flow Margin | 24.58% | 31.12% | 37.30% | 44.34% | 30.95% | 43.15% | Upgrade |
Free Cash Flow Per Share | 2.69 | 3.21 | 3.26 | 3.26 | 1.86 | 2.50 | Upgrade |
Levered Free Cash Flow | 382.75 | 473.88 | 983.13 | 782.25 | 424.38 | 509.38 | Upgrade |
Unlevered Free Cash Flow | 491.5 | 582.63 | 1,064 | 807.25 | 445 | 531.88 | Upgrade |
Change in Net Working Capital | 94 | -51 | -701 | -413 | -105 | -240 | Upgrade |
Updated Feb 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.